Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells

Mol Pharmacol. 2002 Apr;61(4):853-60. doi: 10.1124/mol.61.4.853.

Abstract

Molecular bases for targeting bile acid-cisplatin derivatives Bamet-R2 [cis-diammine-chloro-cholylglycinate-platinum(II)] and Bamet-UD2 [cis-diammine-bisursodeoxycholate-platinum(II)] toward liver cells were investigated. Carriers for bile acids [human Na(+)-taurocholate cotransporting polypeptide (NTCP)], organic anions [organic anion transporting polypeptide (OATP)], and organic cations [organic cation transporter (OCT)] were expressed in Xenopus laevis oocytes (XO) and Chinese hamster ovary (CHO) cells. Drug uptake was measured by flameless atomic absorption of platinum. Rat Oatp1- or rat Ntcp-transfected CHO cells were able to take up Bamets, but not cisplatin, severalfold more efficiently than wild-type cells. This uptake was enhanced by butyrate-induced expression of both carriers. Uptake of both Bamets by Ntcp-transfected CHO cells was stimulated by extracellular sodium. The amount of Bamets, but not cisplatin, taken up by XO was enhanced when expressing OATP-A, OATP-C, NTCP, OCT1, or OCT2, a nonhepatic OCT isoform used for comparative purposes. Bamet uptake by XO was inhibited by known substrates of these carriers (glycocholate for NTCP and OATP-C, ouabain for OATP-A, and quinine for OCT1 and OCT2). Drug uptake versus substrate concentration revealed saturation kinetics (K(m) was in the 8-58 microM range), with the following order of efficiency of transport (V(max)/K(m)) for Bamet-R2: OATP-C > OCT2 > OATP-A > NTCP > OCT1; and the following order of efficiency of transport for Bamet-UD2: OATP-C > OCT2 > OATP-A > OCT1 > NTCP. Increasing the generation of cationic forms of Bamets by incubation in the absence of chloride increased drug uptake by OATP-A, OCT1, and OCT2 but reduced that achieved by NTCP and OATP-C. These results suggest a role for carriers of organic anions and cations in Bamet-R2 and Bamet-UD2 uptake, which may determine their ability to accumulate in liver tumor cells and/or be taken up and efficiently excreted by hepatocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anions / metabolism
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacokinetics*
  • Bile Acids and Salts / metabolism*
  • CHO Cells
  • Cations / metabolism
  • Cricetinae
  • Drug Carriers / pharmacokinetics*
  • Drug Delivery Systems
  • Hepatocytes / metabolism
  • Humans
  • Liver / metabolism*
  • Liver / pathology
  • Oocytes / metabolism
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / pharmacokinetics*
  • Tumor Cells, Cultured
  • Ursodeoxycholic Acid / administration & dosage
  • Ursodeoxycholic Acid / analogs & derivatives*
  • Ursodeoxycholic Acid / pharmacokinetics*
  • Xenopus laevis

Substances

  • Anions
  • Antineoplastic Agents
  • Bamet-UD2
  • Bile Acids and Salts
  • Cations
  • Drug Carriers
  • Organoplatinum Compounds
  • diamminebis(ursodeoxycholate(O,O'))platinum(II)
  • Ursodeoxycholic Acid